Home/ Stocks/ TARS

Tarsus Pharmaceuticals, Inc. Common Stock

TARS XNAS

$61.21 -2.75 (-4.30%) ▼ 15-min delayed

Open

$63.96

High

$64.01

Low

$59.34

Volume

1.01M

Market Cap

$2.63B

About Tarsus Pharmaceuticals, Inc. Common Stock

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 370 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$162.05M	$-6,967,000	$-0.16
FY 2025	$451.36M	$-66,418,000	$-1.59
Q3 2025	$118.70M	$-12,585,000	$-0.30
Q2 2025	$102.66M	$-20,340,000	$-0.48

Earnings & Analyst Ratings

Next Earnings: Tue, Aug 4, 2026

Calendar →

Related Market News

No specific coverage for TARS yet. Check out our latest market news or earnings calendar.

Get TARS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Tarsus Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.